How to Treat Erectile Dysfunction in Men with Diabetes: from Pathophysiology to Treatment

Current Diabetes Reports

Volumn 14, Issue 11, 2014, Pages

  Hatzimouratidis, Konstantinos ^a   Hatzichristou, Dimitrios ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Diabetes; Epidemiology; Erectile dysfunction; Intracavernosal injections; Pathophysiology; Penile prosthesis; Phosphodiesterase inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; VASODILATOR AGENT;

DIABETES MELLITUS; DIABETIC PATIENT; ERECTILE DYSFUNCTION; EXTRACORPOREAL LITHOTRIPSY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PENIS PROSTHESIS; REVIEW; VACUUM ASSISTED CLOSURE; VACUUM ASSISTED CLOSURE DEVICE; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HYPOGONADISM; MALE; MALE GENITAL SYSTEM SURGERY; PATIENT EDUCATION; PROCEDURES; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; TREATMENT OUTCOME;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; PATIENT EDUCATION AS TOPIC; PENILE IMPLANTATION; PENILE PROSTHESIS; PHOSPHODIESTERASE 5 INHIBITORS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84920280306     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0545-6     Document Type: Review

References (91)

1. Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ. 2010;340:c810. doi:10.1136/bmj.c810.
2. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14. doi:10.1016/j.eururo.2010.02.020.
3. Papaharitou S, Athanasiadis L, Nakopoulou E, Kirana P, Portseli A, Iraklidou M, et al. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol. 2006;49(3):557–63. doi:10.1016/j.eururo.2005.09.023.
4. Kirana PS, Rosen R, Hatzichristou D. Subjective well-being as a determinant of individuals’ responses to symptoms: a biopsychosocial perspective. Int J Clin Pract. 2009;63(10):1435–45. doi:10.1111/j.1742-1241.2009.02183.x.
5. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50–6.
6. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3.
7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.
8. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;25(8):1458–63.
9. Hatzimouratidis K, Hatzichristou D. Erectile dysfunction and diabetes mellitus. Insulin. 2009;4(2):114–22.
10. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17(1):39–57. doi:10.1038/sj.ijir.3901250.
11. Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med. 2007;4(4 Pt 1):1046–55. doi:10.1111/j.1743-6109.2007.00530.x.
12. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care. 1998;21(11):1973–7.
13. Fedele D, Coscelli C, Cucinotta D, Forti G, Santeusanio F, Viaggi S, et al. Incidence of erectile dysfunction in Italian men with diabetes. J Urol. 2001;166(4):1368–71.
14. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166(2):213–9. doi:10.1001/archinte.166.2.213.
15. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27(22):2632–9. doi:10.1093/eurheartj/ehl142.
16. Miner M, Seftel AD, Nehra A, Ganz P, Kloner RA, Montorsi P, et al. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J. 2012;164(1):21–8. doi:10.1016/j.ahj.2012.04.006. This is a review showing that identification of ED, particularly in men <60 years old and those with diabetes, is important in early cardiovascular risk detection and reduction.
17. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Urol Clin North Am. 2005;32(4):397-402, v. doi:10.1016/j.ucl.2005.08.005.
18. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163(3):788–91.
19. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol. 2005;96(12B):13M–8. doi:10.1016/j.amjcard.2005.07.005.
20. Esposito K, Giugliano F, Martedi E, Feola G, Marfella R, D’Armiento M, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005;28(5):1201–3.
21. Esposito K, Giugliano F, Maiorino MI, Giugliano D. Dietary factors, Mediterranean diet and erectile dysfunction. J Sex Med. 2010;7(7):2338–45. doi:10.1111/j.1743-6109.2010.01842.x.
22. Burke JP, Jacobson DJ, McGree ME, Nehra A, Roberts RO, Girman CJ, et al. Diabetes and sexual dysfunction: results from the Olmsted County study of urinary symptoms and health status among men. J Urol. 2007;177(4):1438–42. doi:10.1016/j.juro.2006.11.059.
23. Dunsmuir WD, Holmes SA. The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Diabet Med. 1996;13(8):700–8. doi:10.1002/(SICI)1096-9136(199608)13:8<700::AID-DIA174>3.0.CO;2-8.
24. Cellek S, Cameron NE, Cotter MA, Muneer A. Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts. Int J Impot Res. 2013;25(1):1–6. doi:10.1038/ijir.2012.30.
25. Saenz DeTejada I, Angulo J, Cellek S, Gonzalez-Cadavid NF, Heaton J, Pickard R, et al. Physiology of erectile function and pathophysiology of erectile dysfunction. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, editors. Sexual medicine: sexual dysfunctions in men and women. Paris: Health Publications; 2007. p. 287–344.
26. Hecht MJ, Neundorfer B, Kiesewetter F, Hilz MJ. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res. 2001;23(6):651–4. doi:10.1179/016164101101198965.
27. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Tsujimura A, Matsumiya K, et al. Diabetes induced erectile dysfunction and apoptosis in penile crura are recovered by insulin treatment in rats. J Urol. 2003;170(1):291–7. doi:10.1097/01.ju.0000060564.31122.2a.
28. Saenz de Tejada I, Blanco R, Goldstein I, Azadzoi K, de las Morenas A, Krane RJ, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Responses of isolated tissue. Am J Physiol. 1988;254(3 Pt 2):H459–67.
29. Azadzoi KM, Saenz de Tejada I. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol. 1992;148(5):1587–91.
30. Cartledge JJ, Eardley I, Morrison JF. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int. 2001;87(4):394–401.
31. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon. Br J Pharmacol. 1999;128(8):1804–12. doi:10.1038/sj.bjp.0702981.
32. Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res. 2007;19(2):129–38. doi:10.1038/sj.ijir.3901494.
33. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl. 2003;24(6 Suppl):S17–37.
34. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–46. doi:10.1007/s001250051591.
35. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J Urol. 1997;158(5):1966–72.
36. Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990;33(5):306–10.
37. Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem. 2002;277(34):30614–21. doi:10.1074/jbc.M204262200.
38. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004;101(24):9121–6. doi:10.1073/pnas.0400520101.
39. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22(24):8467–77.
40. Simopoulos DN, Gibbons SJ, Malysz J, Szurszewski JH, Farrugia G, Ritman EL, et al. Corporeal structural and vascular micro architecture with X-ray micro computerized tomography in normal and diabetic rabbits: histopathological correlation. J Urol. 2001;165(5):1776–82.
41. Wessells H, Teal TH, Engel K, Sullivan CJ, Gallis B, Tran KB, et al. Fluid shear stress-induced nitric oxide production in human cavernosal endothelial cells: inhibition by hyperglycaemia. BJU Int. 2006;97(5):1047–52. doi:10.1111/j.1464-410X.2006.06059.x.
42. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50(6):1016–26. doi:10.1016/S0090-4295(97)00512-8.
43. Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Viswanathan A, et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol. 2003;170(4 Pt 1):1437–42. doi:10.1097/01.ju.0000077557.45582.f3.
44. Chang S, Hypolite JA, Velez M, Changolkar A, Wein AJ, Chacko S, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R950–60. doi:10.1152/ajpregu.00639.2003.
45. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18(2):190–7. doi:10.1038/sj.ijir.3901391.
46. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–7. doi:10.2337/dc06-1426.
47. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2005;2(1):96–103. doi:10.1111/j.1743-6109.2005.20120.x.
48. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes. 2003;52(9):2353–62.
49. Wessells H. Insights and interventions in diabetes associated erectile dysfunction. J Urol. 2013;190(1):15–6. doi:10.1016/j.juro.2013.04.041.
50. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1(1):6–23. doi:10.1111/j.1743-6109.2004.10104.x.
51. Giugliano D, Giugliano F, Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutr. 2006;9(8A):1118–20. doi:10.1017/S1368980007668542.
52. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978–84. doi:10.1001/jama.291.24.2978.
53. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773–86.
54. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22(7):1208–12.
55. Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol. 2006;50(1):134–40. doi:10.1016/j.eururo.2006.01.042.
56. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–78. doi:10.1016/j.mayocp.2012.06.015.
57. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(2):313–21. doi:10.1016/j.amjcard.2005.03.065.
58. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421–6.
59. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001;44(10):1296–301. doi:10.1007/s001250100656.
60. Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279–84.
61. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–83.
62. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complicat. 2004;18(4):205–10. doi:10.1016/S1056-8727(03)00056-4.
63. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004;47(11):1914–23. doi:10.1007/s00125-004-1549-6.
64. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006;3(5):883–91. doi:10.1111/j.1743-6109.2006.00295.x.
65. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25(2):138–46. doi:10.1111/j.1464-5491.2007.02338.x.
66. Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010;7(8):2842–50. doi:10.1111/j.1743-6109.2010.01888.x.
67. du Moon G, Yang DY, Lee CH, Ahn TY, Min KS, Park K, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011;8(7):2048–61. doi:10.1111/j.1743-6109.2011.02268.x.
68. Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. 2012;87(9):843–52. doi:10.1016/j.mayocp.2012.06.016.
69. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65(12):1621–50.
70. Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR, Osborn DE. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med. 1991;8(10):964–7.
71. Sidi AA, Becher EF, Zhang G, Lewis JH. Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol. 1990;144(5):1154–6.
72. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1–7.
73. Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68(2):386–91. doi:10.1016/j.urology.2006.02.027.
74. Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama a Nijeholt GA, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998;81(6):889–94.
75. Buvat R, Fernando Y, Damaj B, Moncada I, Frank D, Burger M. Clinically significant approvement of erectile function following treatment with alprostadil cream (Vitaros®) in 1652 patients with erectile dysfunction. J Sex Med. 2012;9 suppl 5:384. abstract P-01-086.
76. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13(6):317–21.
77. Perimenis P, Konstantinopoulos A, Perimeni PP, Gyftopoulos K, Kartsanis G, Liatsikos E, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl. 2006;8(2):219–24. doi:10.1111/j.1745-7262.2006.00095.x.
78. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802–15.
79. Tal R, Mulhall JP. Intracavernosal injections and fibrosis: myth or reality? BJU Int. 2008;102(5):525–6. doi:10.1111/j.1464-410X.2008.07738.x.
80. Simmons M, Montague DK. Penile prosthesis implantation: past, present and future. Int J Impot Res. 2008;20(5):437–44. doi:10.1038/ijir.2008.11.
81. Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin North Am. 2007;34(4):535–47. doi:10.1016/j.ucl.2007.08.015. vi.
82. Carson CC. Penile prosthesis implantation: surgical implants in the era of oral medication. Urol Clin North Am. 2005;32(4):503–9. doi:10.1016/j.ucl.2005.09.002. vii.
83. Chen Y, Dai Y, Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother. 2008;9(2):257–66. doi:10.1517/14656566.9.2.257.
84. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006;8(6):675–84. doi:10.1111/j.1745-7262.2006.00223.x.
85. Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169(4):1429–33. doi:10.1097/01.ju.0000056047.74268.9c.
86. Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, McLeod DG. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol. 1992;147(2):386–8.
87. Carson 3rd CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185(2):614–8.
88. Mulcahy JJ, Carson 3rd CC. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol. 2011;60(1):167–72. doi:10.1016/j.eururo.2011.01.046.
89. Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwave treatment of erectile dysfunction. Ther Adv Urol. 2013;5(2):95–9. doi:10.1177/1756287212470696. This is a thorough review of the role of shockwave therapy in the treatment of erectile dysfunction including men with diabetes.
90. Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013;10(3):738–46. doi:10.1111/jsm.12024.
91. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med. 2012;9(1):259–64. doi:10.1111/j.1743-6109.2011.02498.x.